about
Muscle wasting in myotonic dystrophies: a model of premature agingDisease Phenotypes in a Mouse Model of RNA Toxicity Are Independent of Protein Kinase Cα and Protein Kinase CβTWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy.Report on the 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy - September 24-26, 2015, Ottawa, Canada.Hypogonadism Associated with Cyp19a1 (Aromatase) Posttranscriptional Upregulation in Celf1 Knockout Mice.Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblastsMyotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS.Angiotensin-II-induced Muscle Wasting is Mediated by 25-Hydroxycholesterol via GSK3β Signaling Pathway.Reduction of toxic RNAs in myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5Decreased Activity in Neuropathic Pain Form and Gene Expression of Cyclin-Dependent Kinase5 and Glycogen Synthase Kinase-3 Beta in Soleus Muscle of Wistar Male Rats.A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy.Molecular mechanisms of muscle atrophy in myotonic dystrophies.RNA pathogenesis via Toll-like receptor-activated inflammation in expanded repeat neurodegenerative diseases.GSK3β is a new therapeutic target for myotonic dystrophy type 1.Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.Impaired pre-mRNA processing and altered architecture of 3' untranslated regions contribute to the development of human disorders.Molecular mechanisms in DM1 - a focus on foci.Roles for RNA-binding proteins in development and disease.Myotonic dystrophy: approach to therapy.ABLIM1 splicing is abnormal in skeletal muscle of patients with DM1 and regulated by MBNL, CELF and PTBP1.Potential gene regulatory role for cyclin D3 in muscle cells.Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle.Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophy type 1.Detection of expanded RNA repeats using thermostable group II intron reverse transcriptase.Misregulation of calcium-handling proteins promotes hyperactivation of calcineurin-NFAT signaling in skeletal muscle of DM1 mice.Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1.miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models.
P2860
Q26798784-A4444BE3-FD61-4163-A58A-D99897CA1E11Q30275866-A5430D7B-3097-4726-8DF6-41C3BF238F83Q30301119-AA859A13-67CD-4DD3-8BFC-F39819E12F9AQ30355125-AE026DB0-B6F2-49AB-B42A-6F83D45BB4E8Q30360551-F98FA936-4CAF-4D59-9645-7CE2A33970D3Q30830556-454FF8F0-8C92-4317-98E9-5F94C39C5737Q33580885-A2B4DEC2-79AD-44B9-BFE2-5C829E6CC00BQ33809770-55C2E092-D97D-4FF5-8CEA-B63F3A7A7912Q35818784-521F055A-5D80-460E-9D80-6048A3440B6BQ35957963-61915956-9994-43AB-9481-365284EB4373Q36722690-A9416577-01CB-4BC7-8B86-2D188DB0A092Q37103998-2157420D-0F77-4A5C-84E4-0ADE5E59298FQ37138514-72BD1EAA-4E38-462F-99EF-C1FD56049D9FQ37148589-E0CFFB7D-FA8C-4798-A2FD-966B12CFB245Q37590296-24E6150E-743F-4747-AEA9-B3B69F00CAAFQ37610688-08C49548-E65C-4441-BF86-89A5854DF43FQ38125066-3A686384-B087-4D68-B3CE-7649156F4692Q38326275-C8EEB4B3-B594-4589-92CD-A1ABBBB1BF36Q38772987-9182E437-5B1D-4B9C-9C8A-FC516520C5E0Q38855524-AE0D210D-1A0C-4954-A2B9-6EE941CEFF3CQ38939914-99FAAB52-0A45-4BA7-854A-4001EBC9D3F9Q40581150-A9408FD0-FD07-41B8-9409-FFB059499E09Q41702661-19120EEE-2889-4756-89DA-77FF0D2FEEA7Q42866387-14BC7927-E8CB-41C9-9286-E19570FB5540Q47332454-C72D06F5-0291-4128-B4EE-A906593FD126Q49819843-796D11D6-A5DF-4B90-BE62-EBF2AE6834E5Q50755664-133186DF-4BD1-4C97-9C31-50DBDB69BF88Q55240995-234EB1A2-9713-4015-AD22-1B21C725219CQ55418837-F77D87EC-706C-44BD-A74D-8106CAE3145E
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
GSK3β mediates muscle pathology in myotonic dystrophy
@ast
GSK3β mediates muscle pathology in myotonic dystrophy
@en
type
label
GSK3β mediates muscle pathology in myotonic dystrophy
@ast
GSK3β mediates muscle pathology in myotonic dystrophy
@en
prefLabel
GSK3β mediates muscle pathology in myotonic dystrophy
@ast
GSK3β mediates muscle pathology in myotonic dystrophy
@en
P2093
P2860
P50
P356
P1476
GSK3β mediates muscle pathology in myotonic dystrophy
@en
P2093
Christina Wei
James Killian
Karlie Jones
Lubov T Timchenko
Nikolai A Timchenko
Polina Iakova
P2860
P304
P356
10.1172/JCI64081
P407
P577
2012-11-19T00:00:00Z